WELCOME TO C-PATH!
MISSION:
To create innovative collaborations in regulatory science that enable the most efficient and safe medical product development.
VISION:
C-Path is an independent non-profit institute that serves as a "trusted third party" enabling scientists from the FDA, academia and industry to work together for the public good.
Whats New?
June 2010 - Predictive Safety Testing Consortium (PSTC) Announces First-Ever Biomarker Qualification Decision by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA)
June 2010 - Coalition Against Major Diseases Introduces the First Combined Pharmaceutical Trial Data on Neuro-degenerative Diseases
May 2010 - Predictive Safety Testing Consortium Announces Special Issue of Nature Biotechnology
April 2010 - Critical Path Institute President/CEO Receives Award of Excellence
March 2010 - Global Partners Join Forces to Speed Development of New TB Drug Combinations
March 2010 - Critical Path Institute Continues to Expand
What We Do and Why We Do It
Critical Path Institute (C-Path) is an independent, non-profit organization uniquely dedicated to implementing the FDA's Critical Path Initiative by creating collaborations among regulators (scientists from the FDA) and the regulated (medical product industry) that result in accelerated development of safe, new medical products.
A wake-up call: In a 2004 white paper now known as the Critical Path Initiative, the FDA called attention to an alarming decline in the number of innovative medical products being submitted for FDA approval. Click here for more information.
The Institute's Role as a Neutral Third Party
Critical Path Institute's mission from the beginning has been to serve as a "trusted third party" to enable innovative collaborations between government regulators, the academic community and regulated businesses to come together to improve the process of developing new medical products, making the process faster, safer, smarter.